Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

637
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
637
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

952
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
952
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

894
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
894
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
517
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

450
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
450
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.

Gut microbes·2026
Same author

Heritability of Crohn's disease and ulcerative colitis: a Swedish nationwide population-based twin study.

Journal of Crohn's & colitis·2026
Same author

Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study.

Inflammatory bowel diseases·2026
Same author

A novel diagnostic serum protein signature for pediatric inflammatory bowel disease.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.

Gut·2026
Same author

First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study.

Gut microbes·2025

Related Experiment Video

Updated: Jan 15, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

405

IBD Prediction Is Possible, but How Far Are We from Implementing It?

Williams Turpin1,2, Hamed Kalili3, Jonas Halfvarson4

  • 1Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.

Inflammatory Bowel Diseases
|October 13, 2025
PubMed
Summary

Researchers are identifying early biomarkers for inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis. These preclinical indicators, including genetics and proteomics, could enable early detection and prevention strategies for IBD.

Keywords:
Crohn’s diseaseMetabolomicMicrobiomePredictive ModelProteomics

More Related Videos

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.8K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.5K

Related Experiment Videos

Last Updated: Jan 15, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

405
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.8K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.5K

Area of Science:

  • Gastroenterology and Immunology
  • Biomarker Discovery
  • Disease Pathophysiology

Background:

  • Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic gastrointestinal disorders with complex and incompletely understood causes.
  • Identifying preclinical biomarkers is crucial for predicting and potentially preventing IBD.
  • Existing research explores a wide array of potential biomarkers.

Purpose of the Study:

  • To review current research on preclinical biomarkers for IBD.
  • To discuss the application of these biomarkers for early detection and risk stratification.
  • To highlight the potential for personalized IBD prevention strategies.

Main Methods:

  • Review of existing literature on IBD biomarkers.
  • Analysis of genetic, gut permeability, microbiome, proteomic, and metabolomic data.
  • Discussion of integrative risk score development.

Main Results:

  • Proteomic markers (e.g., CXCL9, MMP-10) and pre-diagnostic metabolic changes show promise for IBD.
  • Multiomic data combined with demographic/lifestyle factors can inform personalized risk prediction.
  • Challenges include biomarker data complexity and variability.

Conclusions:

  • Preclinical biomarkers offer significant potential for early IBD detection and risk stratification.
  • Integrative approaches and validated predictive models are key to proactive IBD prevention.
  • Continued research and clinical trials are essential to realize the potential of early risk prediction for reducing IBD incidence.